Neogen Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St

August 01, 2024

Neogen (NASDAQ:NEOG) Full Year 2024 Results

Key Financial Results

Revenue: US$924.2m (up 12% from FY 2023).
Net loss: US$9.42m (loss narrowed by 59% from FY 2023).
US$0.044 loss per share (improved from US$0.12 loss in FY 2023).

revenue-and-expenses-breakdown — NasdaqGS:NEOG Revenue and Expenses Breakdown August 1st 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Neogen Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 1.3%. Earnings per share (EPS) missed analyst estimates by 14%.

The primary driver behind last 12 months revenue was the Food Safety segment contributing a total revenue of US$655.3m (71% of total revenue). The largest operating expense was General & Administrative costs, amounting to US$183.8m (39% of total expenses). Explore how NEOG's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 2.8% p.a. on average during the next 2 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US.

Performance of the American Medical Equipment industry.

The company's share price is broadly unchanged from a week ago.

Balance Sheet Analysis

Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. We've done some analysis and you can see our take on Neogen's balance sheet.

Valuation is complex, but we're here to simplify it.

Discover if Neogen might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com